Estonia - Esti - Ravimiamet

gruenenthal gmbh - rosuvastatiin - õhukese polümeerikattega tablett - 20mg 7tk; 20mg 90tk; 20mg 14tk; 20mg 98tk; 20mg 42tk; 20mg 100tk; 20mg 15tk

Estonia - Esti - Ravimiamet

accord healthcare b.v. - rosuvastatiin - õhukese polümeerikattega tablett - 20mg 500tk; 20mg 60tk; 20mg 28tk; 20mg 90tk; 20mg 30tk; 20mg 7tk

Estonia - Esti - Ravimiamet

zentiva k.s. - rosuvastatiin - õhukese polümeerikattega tablett - 20mg 84tk; 20mg 90tk; 20mg 28tk

Estonia - Esti - Ravimiamet

zentiva k.s. - rosuvastatiin - õhukese polümeerikattega tablett - 10mg 90tk; 10mg 100tk; 10mg 84tk; 10mg 30tk; 10mg 28tk; 10mg 98tk

Estonia - Esti - Ravimiamet

lex ano uab - rosuvastatiin+esetimiib - kõvakapsel - 20mg+10mg 30tk; 20mg+10mg 90tk; 20mg+10mg 60tk

Estonia - Esti - Ravimiamet

ideal trade links uab - rosuvastatiin - õhukese polümeerikattega tablett - 20mg 14tk; 20mg 28tk; 20mg 100tk; 20mg 30tk; 20mg 60tk

Uni Eropa - Esti - EMA (European Medicines Agency)

akebia europe limited - vadadustat - renal insufficiency, chronic; anemia - antianemilised preparaadid - vafseo is indicated for the treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in adults on chronic maintenance dialysis.

Uni Eropa - Esti - EMA (European Medicines Agency)

biogen netherlands b.v. - natalisumab - hulgiskleroos - selektiivsed immunosupressandid - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 ja 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Uni Eropa - Esti - EMA (European Medicines Agency)

sandoz gmbh - natalisumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosupressandid - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 ja 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Uni Eropa - Esti - EMA (European Medicines Agency)

janssen-cilag international n.v.    - ponesimod - sclerosis multiplex, relapsing-remitting - immunosupressandid - ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.